BRPI0814355A2 - Fragmentos de clivagem de imunoglobulina como indicadores de doença e composições para detecção e ligação dos mesmos - Google Patents

Fragmentos de clivagem de imunoglobulina como indicadores de doença e composições para detecção e ligação dos mesmos

Info

Publication number
BRPI0814355A2
BRPI0814355A2 BRPI0814355-2A2A BRPI0814355A BRPI0814355A2 BR PI0814355 A2 BRPI0814355 A2 BR PI0814355A2 BR PI0814355 A BRPI0814355 A BR PI0814355A BR PI0814355 A2 BRPI0814355 A2 BR PI0814355A2
Authority
BR
Brazil
Prior art keywords
cliving
immunoglobulin
fragments
compositions
detection
Prior art date
Application number
BRPI0814355-2A2A
Other languages
English (en)
Inventor
Robert Jordan
Diane D Petrone
Mary Ryan
Original Assignee
Centocor Ortho Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Ortho Biotech Inc filed Critical Centocor Ortho Biotech Inc
Publication of BRPI0814355A2 publication Critical patent/BRPI0814355A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
BRPI0814355-2A2A 2007-08-10 2008-08-04 Fragmentos de clivagem de imunoglobulina como indicadores de doença e composições para detecção e ligação dos mesmos BRPI0814355A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95516207P 2007-08-10 2007-08-10
PCT/US2008/072083 WO2009023457A1 (en) 2007-08-10 2008-08-04 Immunoglobulin cleavage fragments as disease indicators and compositions for detecting and binding such

Publications (1)

Publication Number Publication Date
BRPI0814355A2 true BRPI0814355A2 (pt) 2015-01-27

Family

ID=40351057

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0814355-2A2A BRPI0814355A2 (pt) 2007-08-10 2008-08-04 Fragmentos de clivagem de imunoglobulina como indicadores de doença e composições para detecção e ligação dos mesmos

Country Status (20)

Country Link
US (1) US20090155280A1 (pt)
EP (1) EP2188306B1 (pt)
JP (2) JP5530356B2 (pt)
KR (2) KR20150059813A (pt)
CN (2) CN103497254B (pt)
AU (1) AU2008287128B2 (pt)
BR (1) BRPI0814355A2 (pt)
CA (1) CA2696011A1 (pt)
DK (1) DK2188306T3 (pt)
EA (1) EA025220B1 (pt)
ES (1) ES2593791T3 (pt)
HU (1) HUE029649T2 (pt)
IL (1) IL203544A (pt)
MX (1) MX2010001616A (pt)
NZ (1) NZ582916A (pt)
PL (1) PL2188306T3 (pt)
PT (1) PT2188306T (pt)
SG (1) SG183701A1 (pt)
WO (1) WO2009023457A1 (pt)
ZA (1) ZA201001689B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8501907B2 (en) * 2007-08-10 2013-08-06 Janssen Biotech, Inc. Immunoglobulin cleavage fragments as disease indicators and compositions for detecting and binding such
SG10201407757XA (en) 2009-10-23 2015-01-29 Millennium Pharm Inc Anti-gcc antibody molecules and related compositions and methods
ES2622102T3 (es) 2009-10-29 2017-07-05 Janssen Biotech, Inc. Variantes de anticuerpo de glicosilación
US8041225B2 (en) * 2009-12-21 2011-10-18 General Electric Company Contactless infrared data transmission for wind turbines
CA2818245A1 (en) * 2010-11-19 2012-05-24 Janssen Biotech, Inc. Immunoglobulin cleavage fragments vaccine compositions
ES2623912T3 (es) 2010-12-23 2017-07-12 Janssen Biotech, Inc. Mutantes FC de anticuerpo activo resistente a proteasa
JP5721858B2 (ja) 2010-12-23 2015-05-20 ユーリタ アクチエンゲゼルシャフトＥｕｌｉｔｈａ Ａｇ 大きな面積にわたってナノ構造を製造するためのシステムおよび方法
AU2013251312B2 (en) * 2012-04-27 2018-03-22 Takeda Pharmaceutical Company Limited Anti-GCC antibody molecules and use of same to test for susceptibility to GCC-targeted therapy
US12546782B2 (en) 2013-03-15 2026-02-10 Mayo Foundation For Medical Education And Research Identification and monitoring of monoclonal immunoglobulins related to monoclonal gammopathy by molecular mass with mass spectrometry
MX2016008498A (es) 2013-12-27 2016-10-07 Chugai Pharmaceutical Co Ltd Metodo para purificar anticuerpo que tiene bajo punto isoelectrico.
CA2944767C (en) 2014-04-04 2022-07-12 Mayo Foundation For Medical Education And Research Isotyping immunoglobulins using accurate molecular mass
EP3353200A4 (en) 2015-09-24 2019-06-26 Mayo Foundation for Medical Education and Research IDENTIFICATION OF FREE LIGHT CHAINS FROM IMMOBILIZED LOBULIN BY MASS SPECTROMETRY
AU2017325022B2 (en) 2016-09-07 2022-10-13 Mayo Foundation For Medical Education And Research Identification and monitoring of cleaved immunoglobulins by molecular mass
US11946937B2 (en) 2017-09-13 2024-04-02 Mayo Foundation For Medical Education And Research Identification and monitoring of apoptosis inhibitor of macrophage
US12153052B2 (en) 2017-09-13 2024-11-26 Mayo Foundation For Medical Education And Research Identification and monitoring of immunoglobulin J chains
US12428496B2 (en) * 2017-12-07 2025-09-30 Chugai Seiyaku Kabushiki Kaisha Antibodies, compositions for use in detecting or capturing a polypeptide in a sample, and methods for detecting or capturing a polypeptide in a sample
US20210325380A1 (en) * 2020-04-20 2021-10-21 EnLiSense, LLC Disease diagnostics using a multi-configurable sensing array

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2162863T3 (es) * 1993-04-29 2002-01-16 Unilever Nv Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
AUPM322393A0 (en) * 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US7129331B2 (en) * 2000-05-31 2006-10-31 Pestka Biomedical Laboratories, Inc. Phosphorylated polypeptides and uses related thereto
GB0130228D0 (en) * 2001-12-18 2002-02-06 Hansa Medica Ab Protein

Also Published As

Publication number Publication date
EP2188306A4 (en) 2011-03-02
PL2188306T3 (pl) 2017-01-31
JP2014058535A (ja) 2014-04-03
ES2593791T3 (es) 2016-12-13
PT2188306T (pt) 2016-09-13
HUE029649T2 (en) 2017-02-28
KR20100059850A (ko) 2010-06-04
KR101588276B1 (ko) 2016-01-26
JP2010536037A (ja) 2010-11-25
KR20150059813A (ko) 2015-06-02
SG183701A1 (en) 2012-09-27
EA025220B1 (ru) 2016-12-30
MX2010001616A (es) 2010-03-15
CN103497254B (zh) 2016-12-28
EP2188306A1 (en) 2010-05-26
AU2008287128A1 (en) 2009-02-19
US20090155280A1 (en) 2009-06-18
IL203544A (en) 2015-07-30
ZA201001689B (en) 2011-06-29
NZ582916A (en) 2012-08-31
WO2009023457A1 (en) 2009-02-19
JP5530356B2 (ja) 2014-06-25
CA2696011A1 (en) 2009-02-19
CN101889021A (zh) 2010-11-17
DK2188306T3 (en) 2016-08-22
EP2188306B1 (en) 2016-06-29
EA201070236A1 (ru) 2010-08-30
CN101889021B (zh) 2016-06-08
AU2008287128B2 (en) 2013-07-18
CN103497254A (zh) 2014-01-08

Similar Documents

Publication Publication Date Title
BRPI0814355A2 (pt) Fragmentos de clivagem de imunoglobulina como indicadores de doença e composições para detecção e ligação dos mesmos
BRPI0820980A2 (pt) Composições e métodos para detecção de tiabs
HRP20180572T1 (hr) 1' -supstituirani karba-nukleozidni analozi za antivirusnu terapiju
PT2963031T (pt) Pró-fármacos de tetrahidrocanabinol, composições compreendendo pró-fármacos de tetrahidrocanabinol e métodos de utilização dos mesmos
PT2424896E (pt) Anticorpos anti-ceacam1 e métodos de utilização dos mesmos
PT2144998T (pt) Métodos e composições para vírus vivos atenuados
BRPI0813725A2 (pt) Métodos e composições para tratamento de doenças
BR112012001666A2 (pt) composições de proteína rsv f e métodos para fazer as mesmas
BRPI0819909A2 (pt) anticorpos antimesotelina e usos dos mesmos
BRPI0811635A2 (pt) Compostos de arilazol-2-il cianoetilamino, métodos para fazê-los e métodos para o uso dos mesmos
BRPI1010024A2 (pt) derivados de aminopirrolidinona e uso dos mesmos
PT2427212T (pt) Anticorpos anti-cd100 e métodos para utilização dos mesmos
EP2021192A4 (en) IMPROVED SCISSOR
BRPI0912480A2 (pt) compostos de monoalquiltina de alta pureza e usos dos mesmos
BR112012001260A2 (pt) conjugados de epsilon-polilisina e o emprego dos mesmos
HUE043040T2 (hu) Poliszacharid keresztkötéseket tartalmazó fehérje készítmény és/vagy formula
BRPI0920927A2 (pt) derivados de azaquinolinona e usos dos mesmos
BRPI1013642A2 (pt) derivado de triazina e composição farmacêutica compreendendo o mesmo
BRPI1008661A2 (pt) derivados e remédios de aminopirazina
BRPI0912198A2 (pt) anticorpos anti-fn14 e usos dos mesmos
PT3443970T (pt) Fagos antibacterianos, péptidos fágicos e métodos de utilização dos mesmos
BRPI1009455A2 (pt) anticorpos anti-c40 e usos dos mesmos
BRPI0815588A2 (pt) Compostos de poliorganossiloxano-poliuréia e/ou de poliorganossilo-xano-poliuretano
BRPI1014099A2 (pt) alvo bioabsorvível para procedimento de diagnóstico ou terapêutico
BRPI1008566A2 (pt) métodos e composições para o diagnóstico e tratamento de câncer

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2525 DE 28-05-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.